Back

Targeting Interferon-Driven Inflammatory Memory Prevents Epigenetic Evolution of Cancer Immunotherapy Resistance

Qiu, J.; Ye, D.; Chen, X. E.; Dangle, N.; Yoshor, B.; Zhang, T.; Shao, Y.; Nallamala, V. C.; Wang, S.; Ren, D.; Xu, Y.; Chen, J.; Zhang, N. R.; Shi, J.; Greenberg, R. A.; Minn, A. J.

2024-08-16 immunology
10.1101/2024.08.13.607862 bioRxiv
Show abstract

Acquired resistance is a growing obstacle to durable responses after cancer immune checkpoint blockade (ICB). The mechanisms by which heterogeneous tumors evolve under immunotherapy pressure and strategies targeting key populations to prevent relapse are poorly understood. We show that chronic interferon (IFN) enables a subpopulation of cancer cells to acquire inflammatory memory and express memory ISGs, a subset of IFN-stimulated genes enriched for immune evasion properties, leading to subclonal epigenetic evolution of ICB-resistant states. Inflammatory memory is epigenetically encoded through chronic virus mimicry - feedforward MDA5 signaling likely activated by endogenous retroelements. While JAK inhibitors can improve ICB response, combining them with TBK1 inhibitors collapses this feedforward mechanism, erasing inflammatory memory and preventing differentiation into resistance states. Across human cancers, small subpopulations of memory ISG-expressing cells are prevalent and coupled to T cell exhaustion, suggesting inflammatory memory may be a common mechanism of acquired resistance targetable by JAK plus TBK1 inhibition.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Immunology
○ 79 papers in training set
Top 0.1%
14.9%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 14%
12.7%
Similar papers in this journal
3
Cell Reports
○ 1498 papers in training set
Top 2%
10.5%
Similar papers in this journal
4
Cell
○ 431 papers in training set
Top 0.6%
7.8%
Similar papers in this journal
5
Nature
○ 645 papers in training set
Top 2%
7.8%
Similar papers in this journal
50% of probability mass above
6
Immunity
○ 67 papers in training set
Top 0.2%
5.4%
7
Science Advances
● 1243 papers in training set
Top 6%
4.8%
8
Science Immunology
● 88 papers in training set
Top 0.7%
4.0%
9
eLife
● 5828 papers in training set
Top 33%
3.4%
10
Journal of Experimental Medicine
● 119 papers in training set
Top 1%
2.4%
11
Molecular Cell
○ 350 papers in training set
Top 2%
2.4%
12
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 26%
1.9%
13
Cancer Discovery
● 66 papers in training set
Top 1%
1.7%
14
Science
● 477 papers in training set
Top 5%
1.7%
15
Cancer Cell
○ 42 papers in training set
Top 1%
1.1%
16
Cell Reports Medicine
○ 153 papers in training set
Top 4%
1.0%
17
Cell Systems
○ 201 papers in training set
Top 5%
0.8%
18
Science Translational Medicine
● 127 papers in training set
Top 4%
0.8%
19
Cancer Research
● 130 papers in training set
Top 3%
0.8%
20
Nature Cell Biology
○ 118 papers in training set
Top 3%
0.8%
21
iScience
○ 1154 papers in training set
Top 37%
0.8%
22
Cell Host & Microbe
126 papers in training set
Top 2%
0.8%
23
Cancer Immunology Research
● 35 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.